Abstract
Among solid tumors, breast cancer has been a model of the benefit of targeted therapies, particularly with trastuzumab which reversed the prognosis of patients with HER-2 positive tumor, opening the way to the development of other anti-HER2 targeted therapies and a antibody-drug conjugate. The past two years have seen the arrival of a specific pharmaceutical form of trastuzumab, allowing subcutaneously and fixed-dose administration. Attention has also been paid to a second targeted biotherapy in breast cancer: bevacizumab. Data from IMELDA and TANIA studies pose questions, and provide answers, on the administration sequence as compared to chemotherapy and the maintenance of antiangiogenic pressure using bevacizumab in this type of tumor. We propose here a review of data from the past two years on these two drugs in this indication.
| Translated title of the contribution | New data and updates on targeted biotherapies in breast cancer |
|---|---|
| Original language | French |
| Pages (from-to) | 99-112 |
| Number of pages | 14 |
| Journal | Journal de Pharmacie Clinique |
| Volume | 34 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 Jan 2015 |
| Externally published | Yes |